arrow
K

Kamran A. Ahmed

Roswell Park Comprehensive Cancer Center
H指数:37
被引数:4,545

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A A FIRST IN HUMAN PHASE I TRIAL OF INTRATHECAL DENDRITIC CELLS PRIMED AGAINST HER2/HER3 IN PATIENTS WITH LEPTOMENINGEAL DISEASE FROM TRIPLE-NEGATIVE OR HER2+BREAST CANCER SHOW DEVELOPMENT OF ADAPTIVE IMMUNE RESPONSES

一项首次人体I期临床试验,评估鞘内注射针对HER2/HER3的树突状细胞在来自三阴性或HER2+乳腺癌患者的软脑膜疾病患者中诱导适应性免疫反应的发展。

2025-10-010
OAAI
Sacituzumab govitecan and stereotactic radiosurgery in the management of HER2 negative breast cancer brain metastases: a multi-institutional report

Sacituzumab govitecan和立体定向放射手术治疗HER2阴性乳腺癌脑转移瘤:一项多中心报告

2025-09-300
PRE
ASO Visual Abstract: Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial

ASO视觉摘要:新辅助化疗对浸润性小叶乳腺癌手术结果及淋巴结阴性转化率的影响:根据I-SPY2临床试验中分子高风险肿瘤的组织学亚型进行分析

2025-08-230
PRE
Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial

新辅助化疗对浸润性小叶乳腺癌手术结果及淋巴结阴性转化影响的评估:基于I-SPY2临床试验中按组织学亚型分析分子高风险肿瘤

2025-07-240
OA
Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial

在多中心新辅助I-SPY2试验中,基于自我识别种族的腋窝手术管理差异

2025-07-230
OA
Association between transcriptomic metrics of exogenous antigen presentation and adaptive immunity with locoregional recurrence in localized estrogen receptor negative breast cancer: retrospective review of multi-institutional datasets

外源性抗原呈递转录组学指标与适应性免疫在局部雌激素受体阴性乳腺癌局部区域复发中的关联:多中心数据集的回顾性研究

2025-05-130
OA
Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: long-term results and biomarker analysis from a non-randomized, open-label, phase Ib study

Nivolumab和立体定向放射外科治疗乳腺癌脑转移患者:一项非随机、开放标签、Ib期研究的长期结果和生物标志物分析

2025-04-280
OA
Phase II trial of brain MRI surveillance in stage IV breast cancer

IV期乳腺癌中脑MRI监测的II期临床试验

2025-01-240
PRE
Multi-institutional report of trastuzumab deruxtecan and stereotactic radiosurgery for HER2 positive and HER2-low breast cancer brain metastases
2024-11-211
OA
Phase II Study of Genomically Guided Radiation Dose Personalization in the Management of Triple Negative Breast Cancer
2024-05-020
PRE
Habitat escalated adaptive therapy (HEAT): a phase 2 trial utilizing radiomic habitat-directed and genomic-adjusted radiation dose (GARD) optimization for high-grade soft tissue sarcoma

栖息地升级适应性治疗 (HEAT): 一项2期试验,利用放射性栖息地导向和基因组调整辐射剂量 (GARD) 优化治疗高级软组织肉瘤

2024-04-094
OAAI
Clinical outcomes of melanoma brain metastases treated with nivolumab and ipilimumab alone versus nivolumab and ipilimumab with stereotactic radiosurgery

单独使用nivolumab和ipilimumab与nivolumab和ipilimumab进行立体定向放射外科治疗的黑色素瘤脑转移的临床结果

2024-02-033
PRE
Stereotactic radiosurgery and anti-PD-1+CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitors, or conventional chemotherapy for the management of melanoma brain metastases
2023-10-014
OA